These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37783810)

  • 1. Discontinued CRISPR gene therapy for sickle-cell disease improves symptoms.
    Carvalho T
    Nat Med; 2023 Nov; 29(11):2669-2670. PubMed ID: 37783810
    [No Abstract]   [Full Text] [Related]  

  • 2. Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.
    Harris E
    JAMA; 2024 Jan; 331(4):280. PubMed ID: 38170544
    [No Abstract]   [Full Text] [Related]  

  • 3. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Mehta J
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107196
    [No Abstract]   [Full Text] [Related]  

  • 4. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Meisel R
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107195
    [No Abstract]   [Full Text] [Related]  

  • 5. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply.
    Frangoul H; Ho TW; Corbacioglu S
    N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107197
    [No Abstract]   [Full Text] [Related]  

  • 6. CRISPR gene therapy shows promise against blood diseases.
    Ledford H
    Nature; 2020 Dec; 588(7838):383. PubMed ID: 33299166
    [No Abstract]   [Full Text] [Related]  

  • 7. Perspectives of Sickle Cell Disease Stakeholders on Heritable Genome Editing.
    Hollister BM; Gatter MC; Abdallah KE; Armsby AJ; Buscetta AJ; Byeon YJJ; Cooper KE; Desine S; Persaud A; Ormond KE; Bonham VL
    CRISPR J; 2019 Dec; 2(6):441-449. PubMed ID: 31742431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug pipeline 3Q23 - ERT, bispecifics and CRISPR in sickle cell disease.
    Hodgson J
    Nat Biotechnol; 2023 Nov; 41(11):1498-1500. PubMed ID: 37950006
    [No Abstract]   [Full Text] [Related]  

  • 10. Gene therapy for sickle cell disease.
    The Lancet Haematology
    Lancet Haematol; 2016 Oct; 3(10):e446. PubMed ID: 27692301
    [No Abstract]   [Full Text] [Related]  

  • 11. Rationally Designed Base Editors for Precise Editing of the Sickle Cell Disease Mutation.
    Chu SH; Packer M; Rees H; Lam D; Yu Y; Marshall J; Cheng LI; Lam D; Olins J; Ran FA; Liquori A; Gantzer B; Decker J; Born D; Barrera L; Hartigan A; Gaudelli N; Ciaramella G; Slaymaker IM
    CRISPR J; 2021 Apr; 4(2):169-177. PubMed ID: 33876959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.
    Parums DV
    Med Sci Monit; 2024 Mar; 30():e944204. PubMed ID: 38425279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR in personalized medicine: Industry perspectives in gene editing.
    Hong A
    Semin Perinatol; 2018 Dec; 42(8):501-507. PubMed ID: 30376985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment by CRISPR-Cas9 Gene Editing - A Proof of Principle.
    Malech HL
    N Engl J Med; 2021 Jan; 384(3):286-287. PubMed ID: 33471982
    [No Abstract]   [Full Text] [Related]  

  • 15. The promise and challenge of therapeutic genome editing.
    Doudna JA
    Nature; 2020 Feb; 578(7794):229-236. PubMed ID: 32051598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-based gene-editing technology for sickle cell disease.
    Ma L; Yang S; Peng Q; Zhang J; Zhang J
    Gene; 2023 Jul; 874():147480. PubMed ID: 37182559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9: A revolution in genome editing in rheumatic diseases.
    Duroux-Richard I; Giovannangeli C; Apparailly F
    Joint Bone Spine; 2017 Jan; 84(1):1-4. PubMed ID: 27825565
    [No Abstract]   [Full Text] [Related]  

  • 20. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.